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Introduction
Given the negative fundamental effect pain can have
on quality of life (QoL), the philosophy underpin-
ning the World Health Organization’s (WHO’s)
three-step analgesic ladder is to free patients from
pain (1). This compassionate position supports an
aggressive approach to pain management, with pro-
gressively stronger analgesics recommended until
relief is achieved.
As many cancer patients suffer from moderate-to-
severe pain, opioids are the mainstay of analgesic
therapy for treating this population (2). Opioid anal-
gesics are also used for the treatment of chronic
non-cancer-related pain, including musculoskeletal
and neuropathic pain (3). While there is a paucity of
good-quality research concerning the risks and bene-
ﬁts of the long-term use of opioids for chronic non-
cancer pain, their efﬁcacy per se is acknowledged in
these patients (4).
Surveys of treatments for pain, either related to can-
cer or non-related, have revealed wide variations in
the use of opioids across countries (5,6). Irrespective
of these variations, a large number of patients are
currently receiving opioid therapy for chronic pain.
Globally, it has been estimated that a total of 365
million prescriptions were written for opioids in
2005 [235 million prescriptions in the USA (7), 66
million in the EU and 64 million in the rest of the
world (8)]. A substantial proportion of these pre-
scriptions were for chronic pain: in the USA 20% of
prescriptions were for opioid therapy of over
30 days’ duration (7).
A large-scale computer-assisted telephone survey
was recently undertaken to explore the prevalence,
severity, treatment and impact of chronic pain (6).
The survey, conducted in 15 European countries and
Israel, found that chronic pain of moderate-to-severe
intensity occurred in 19% of adults, seriously affect-
ing the quality of their social and working lives.
Approximately 60% of those reporting moderate-to-
severe pain had experienced the problem for
2–15 years, and 70% were under the care of their
family doctors/general practitioners for pain manage-
ment. More than half (52%) of chronic pain suf-
ferers were taking some form of prescription
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SUMMARY
As a result of the undesired action of opioids on the gastrointestinal (GI) tract,
patients receiving opioid medication for chronic pain often experience opioid-
induced bowel dysfunction (OBD), the most common and debilitating symptom of
which is constipation. Based on clinical experience and a comprehensive MEDLINE
literature review, this paper provides the primary care physician with an overview
of the prevalence, pathophysiology and burden of OBD. Patients with OBD suffer
from a wide range of symptoms including constipation, decreased gastric emptying,
abdominal cramping, spasm, bloating, delayed GI transit and the formation of hard
dry stools. OBD can have a serious negative impact on quality of life (QoL) and
the daily activities that patients feel able to perform. To relieve constipation associ-
ated with OBD, patients often use laxatives chronically (associated with risks) or
alter/abandon their opioid medication, potentially sacriﬁcing analgesia. Physicians
should have greater appreciation of the prevalence, symptoms and burden of OBD.
In light of the serious negative impact OBD can have on QoL, physicians should
encourage dialogue with patients to facilitate optimal symptomatic management of
the condition. There is a pressing need for new therapies that act upon the under-
lying mechanisms of OBD.
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steroidal anti-inﬂammatory drugs (44% patients);
strong opioids were used by 5% of the 46,394
patients surveyed (6).
The aim of palliative care is to improve the QoL
of patients (and their families) who face life-threat-
ening illness. In addition to providing spiritual and
psychosocial support, patients should be offered
effective symptom and pain relief (1). Therefore, the
use of opioid analgesics is unsurprisingly very com-
mon in the palliative care setting. For example, in
the US, opioid pain medications are used in the ter-
minal phase of care for more than 50% of cancer
patients (9).
While opioids are the gold standard for treating
pain when analgesics such as acetaminophen and
aspirin do not achieve adequate control (1), adverse
effects compromise their therapeutic potential. The
gastrointestinal (GI) tract is a signiﬁcant site of
opioid-related adverse effects due to the presence of
opioid receptors, whose activation by exogenous
opioids, in particular, disrupts GI motility and
secretion, thereby inhibiting normal bowel function
(10). This action commonly causes bothersome GI
side effects, the most common of which is constipa-
tion; others include decreased gastric emptying
(leading to gastro-oesophageal reﬂux/heartburn),
abdominal cramping, spasm, bloating, delayed GI
transit and the formation of hard dry stools. In
turn, this can cause straining, painful defection,
incomplete evacuation and a sensation of anorectal
bowel obstruction (10–13). The action of opioids
on the GI tract is also thought to contribute to
nausea and vomiting (14). However, in contrast to
nausea and vomiting, patients rarely develop toler-
ance to the constipation-related adverse effects of
opioid use (13,15). In addition to GI effects, pro-
longed opioid therapy can lead to cellular and intra-
cellular changes, which may contribute to
pharmacologic opioid tolerance and/or increased
sensitivity to pain (manifested as apparent opioid
tolerance), resulting in the need for dose escalation.
Prolonged opioid treatment may also result in hor-
monal changes, such as reduced testosterone and
oestrogen levels, and may even alter immune func-
tion (16).
The constellation of GI signs and symptoms asso-
ciated with opioids is referred to as opioid-induced
bowel dysfunction (OBD) (13,17). OBD, the most
common and often most debilitating symptom of
which is constipation, can have a signiﬁcant adverse
impact on patients taking opioids (13,15). This paper
will provide an overview of the pathogenesis and
burden of OBD and will summarise current manage-
ment strategies.
Pathophysiology
To understand the basis of OBD, the physiology of the
GI tract and the role of the endogenous opioid system
in the alimentary canal must be considered. The GI
tract is innervated by the enteric nervous system,
which is composed of the myenteric plexus, located
between circular and longitudinal smooth muscle
layers of the bowel, and the submucosal plexus,
located in the submucosa (10,18). Enteric neurons
also synthesise opioid peptides and their transmitters.
Met-enkephalin, leu-enkephalin, b-endorphin and
dynorphin are examples of endogenous opioids pre-
sent in the GI tract, where they have been localised
to both neurons and endocrine cells of the mucosa
(10). Studies in animals and humans suggest that
endogenous opioids inhibit enteric nerve activity and
inhibit both propulsive motor and secretory activities
(10,11). Therefore, endogenous opioids in the GI
tract appear to function to co-ordinate the contract-
ile process under normal conditions and suppress
intestinal motility when required (such as during
inﬂammation, stress and trauma) (10,19).
Immunocytochemistry and mRNA quantiﬁcation
techniques have identiﬁed receptors that mediate the
effects of both endogenous and exogenous opioids
on bowel function (10,18). Three major and distinct
classes of opioid receptors are located in the enteric
nervous system: delta, kappa and mu (20,21). Of
these three receptor classes, the enteric mu-opioid
receptor appears to be the principal mediator of opi-
oid agonist effects on the GI tract (20,22). When
opioid agonists bind to these receptors, the release of
excitatory and inhibitory neurotransmitters is inhib-
ited. This interrupts the co-ordinated rhythmic con-
tractions required for intestinal motility and reduces
mucosal secretions (23,24). Administration of exo-
genous opioids can cause OBD by decreasing peri-
stalsis (11), which in combination with reduced
secretions into the gut and increased reabsorption of
ﬂuid from the gut (as the stool remains in the intes-
tinal lumen for extended periods) leads to the forma-
tion of dry, hard stools that are difﬁcult to pass.
Burden of OBD
The burden of OBD is a function of its prevalence as
well as its negative impact on health-related QoL.
While the existence of OBD is undisputed, its wider
impact is likely underestimated by healthcare profes-
sionals (25), particularly because most OBD symp-
toms persist for as long as opioid therapy is
administered. The physical sequelae of constipation,
some of which can very occasionally be life threaten-
ing, also demand consideration when assessing the
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and fecal impaction contribute to the burden of the
condition and often require treatment (26).
Constipation is the most common and often most
debilitating adverse effect associated with opioid
therapy for the management of chronic pain (13,15).
Perhaps because of this, estimates of the prevalence
of OBD are largely based on the frequency of this
primary symptom (13). To assess the true prevalence
of OBD, there is clearly a need for large-scale, pros-
pective studies that use a standardised deﬁnition of
the condition that embraces all symptoms of OBD.
Estimates of the frequency of constipation vary
from 15–90% in patients receiving opioids for non-
cancer pain (12,3,27). A meta-analysis of available
randomised, placebo-controlled trials of non-cancer
patients receiving opioids for moderate-to-severe
pain revealed that approximately 80% of patients
experienced at least one adverse event, with constipa-
tion (41%) and nausea (32%) being the most com-
mon opioid-related side effects (3). However,
according to a systematic review of 34 randomised,
controlled trials of oral opioids, 15% of patients
reported constipation (12). The difference between
these two analyses can be attributed to the exclusion
of trials of ‘weak’ opioids, such as codeine and tra-
madol, in the former study and the inclusion of
comparator trials in the latter. A higher rate of con-
stipation (90%) was reported in a multicentre, inter-
national, open-label, crossover trial comparing the
efﬁcacy and tolerability of transdermal fentanyl and
sustained release oral morphine in 256 patients aged
26–82 years with chronic non-cancer pain (27).
It is particularly challenging to obtain accurate
estimates of the prevalence of constipation caused by
opioid therapy in cancer patients because of numer-
ous other factors that may also induce the condition.
These include physiologic causes such as dehydra-
tion, metabolic disturbances such as hyperkalaemia,
mechanical causes such as tumour and psychological
factors. However, it is clear that cancer patients
experience constipation relating to opioid use, and
that existing disease-related constipation can be
exacerbated by opioid therapy (13,28).
The prevalence of OBD symptoms, including con-
stipation, was assessed in 593 cancer patients receiv-
ing treatment according to WHO guidelines (29).
Constipation was one of the most frequent side
effects of opioid treatment, observed in 23% of
patients. Another series of studies conducted in a
large US hospice found that 40–63% of patients with
cancer had opioid-induced constipation (25). The
higher rate (63%) was derived from retrospective
patient reports; the lower rate corresponded to data
obtained from a chart audit (40%).
Much of this wide variation in the frequency of
opioid-induced constipation can be attributed to
study design and population heterogeneity. Study
populations vary with respect to age, gender and
underlying pathology. Choice of opioid, route of
administration, dose and the duration of treatment
all contribute to variation in the frequency of side
effects. Subjectivity introduces additional variation:
people’s perceptions of constipation vary, as does
their approach to the management of symptoms. A
fundamental reason why reported rates of constipa-
tion vary so greatly is that no single deﬁnition of
constipation is universally applied. While many study
protocols, for reasons of convenience and consis-
tency, deﬁne constipation as fewer than three bowel
movements per week, attempts have been made to
reﬁne the deﬁnition by taking a more comprehensive
approach. For example, the Rome diagnostic criteria
for constipation not only encompass bowel move-
ment frequency, but also capture the discomfort
associated with constipation (Table 1) (30). This
more comprehensive deﬁnition should ideally form
the basis of any tool used to assess constipation asso-
ciated with OBD.
Impact of OBD
Evidence shows that the long-term use of opioids for
chronic pain can lead to improvements in patients’
QoL (28,31). However, the side effects of opioid
therapy, e.g. constipation, are likely to limit this
beneﬁt (9). Illustrating this point, one survey has
indicated that constipation is ranked by the majority
of cancer patients as an even more common source
of distress than the pain they are suffering (32). It
has also been suggested that some patients receiving
long-term opioid treatment for pain would rather
endure their pain than the constipation opioids may
cause (9).
Attempts have been made to quantify the impact
of OBD on health-related QoL (33,34). The Patient
Reports of Opioid-related Bothersome Effects survey
– a web-based cross-sectional survey of 161 chronic
pain patients in the USA taking oral opioids and
generally using laxatives – was conducted to charac-
terise the prevalence, frequency and severity of OBD
symptoms, and their impact on QoL and activities of
daily living (ADL). Participants were asked to iden-
tify any GI side effects they had experienced during
opioid treatment, and rate the impact of each symp-
tom on QoL and ADL on a ﬁve-point scale. The
most common side effect was constipation, with
85–95% and 74–92% of these constipated patients
reporting some degree of negative impact on QoL
and ADL, respectively (35). OBD symptoms other
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cuation and heartburn, have similarly been reported
to have a signiﬁcant detrimental impact on QoL and
ADL (36).
Results of the 2004 National Health and Wellness
Survey (a large, international survey that captured
self-reported information on how patients use
healthcare services) were used to assess the impact of
opioid-induced constipation on healthcare resource
utilisation, work productivity, and activity impair-
ment in a sample of 2420 patients who had been tak-
ing opioids for ‡ 6 months for chronic pain (37).
Compared with non-constipated patients, opioid-
treated patients with constipation were more likely
to visit physicians, miss work, feel that their per-
formance at work was impaired and that symptoms
impaired their ability to undertake daily activities
(37).
Ultimately, OBD can impact the use of opioid
medication. Patients may discontinue opioid therapy
because of symptoms of OBD (3,17,38), which can
pose challenges in achieving pain therapy goals.
Evaluation and treatment of OBD
Evaluation of OBD
Two constipation-speciﬁc instruments are available
for patients to assess the impact and severity of the
condition: the Patient Assessment of Constipation
Quality of Life (PAC-QOL) and the Patient Assess-
ment of Constipation Symptoms (PAC-SYM) ques-
tionnaires. The PAC-QOL instrument was developed
to address the need for a standardised, patient-repor-
ted outcomes measure to evaluate the burden of
constipation on patients’ everyday functioning and
well-being over time, while the PAC-SYM instrument
is used to assess the symptoms and severity of consti-
pation. The PAC-QOL and PAC-SYM instruments
have been shown to be reliable, valid and responsive
measures of constipation and opioid-induced consti-
pation respectively (39,40). Use of these brief and
easy-to-administer questionnaires may help to char-
acterise the extent and burden of OBD and thereby
encourage a more active approach to treatment of
the condition.
Treatment of OBD
After OBD has been recognised, steps should be
taken to manage the condition; however, there are
currently no detailed and widely accepted guidelines
for the management of OBD. A well-recognised
source of guidance is the European Association of
Palliative Care Research Network (EAPC) who have
published recommendations for treating adverse
effects associated with opioids (41,42).
The EAPC recommends the following strategies
for managing general adverse effects associated with
oral morphine: reducing opioid dose, rotating opi-
oids, changing the route of administration and
symptomatic management (41). Unfortunately, each
of these strategies appears to have limited beneﬁt for
most patients with OBD. The obvious disadvantage
of reducing opioid dose is that analgesia may be
compromised. Although there is much anecdotal and
observational data to support switching opioids in
the event of inadequate pain relief and/or intolerable
side effects, there is a lack of randomised trials to
vindicate this approach for reducing OBD (43).
Similarly, although there is some evidence that trans-
dermal administration of opiates such as fentanyl
Table 1 Rome II and III criteria for chronic constipation (30)
Diagnostic criteria Symptoms
Rome II
In at least 12 weeks, which need not be consecutive,
in the preceding 12 months, ‡ 2 symptoms must be present
• Straining in > 25% of bowel movements
• Hard or lumpy stools in > 25% of bowel movements
• Sensation of incomplete evacuation in > 25% of bowel movements
• Sensation of anorectal obstruction/blockade in > 25% of bowel movements
• Manual manoeuvres to facilitate > 25% of bowel movements (digital disimpaction)
• < 3 bowel movements per week
• Loose stool is not present, and criteria for irritable bowel syndrome are not fulﬁlled
Rome III
Presence of ‡ 2 symptoms
• Straining during ‡ 25% of defecations
• Lumpy or hard stools in ‡ 25% of defecations
• Sensation of incomplete evacuation for ‡ 25% of defecations
• Sensation of anorectal obstruction/blockage for ‡ 25% of defecations
• Manual manoeuvres to facilitate ‡ 25% of defecations (digital manipulations, pelvic ﬂoor support)
• < 3 evacuations per week
• Loose stools are rarely present without the use of laxatives
• Insufﬁcient criteria for irritable bowel syndrome
• Criteria fulﬁlled for the last 3 months, and symptom onset ‡ 6 months prior to diagnosis
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QoL than oral morphine (27), contradictory data
also exist (44).
Symptomatic management
Addressing the individual symptoms of OBD (such
as nausea, vomiting, gastric reﬂux and constipation-
related symptoms) is currently the most viable
option for relieving the condition. Understanding the
mechanisms that cause OBD symptoms should
inform treatment selection (45).
Nausea and vomiting associated with opioid use
occur in approximately 25% of patients and tend to
resolve over time. Patients who develop persistent,
signiﬁcant nausea/vomiting or are not satisﬁed with
the approach of waiting for symptoms to resolve will
likely beneﬁt from an anti-emetic treatment with a
prokinetic agent, such as metoclopramide, a dop-
amine antagonists or serotonin antagonist (45). To
treat the gastro-oesophegeal reﬂux associated with
OBD, over-the-counter antacid and/or alginate prep-
arations can provide effective symptom relief in
many patients. Low-dose histamine H2-receptor
antagonists can also provide effective symptomatic
relief, particularly in patients with milder symptoms.
If these steps fail to provide adequate relief, proton
pump inhibitors may be considered. These are agents
of choice for the suppression of gastric acid produc-
tion and have become the mainstay of therapy for
acid-related diseases in general (46), although their
utility in an OBD population has yet to be validated.
Current non-pharmacologic strategies for the con-
stipation associated with OBD include interventions
such as increased dietary ﬁbre and ﬂuid intake,
encouraging mobility and ambulation and encour-
aging daily bowel movements at the same time every
day (13,45). However, pharmacologic approaches are
often necessary. Laxatives are most frequently used
to promote bowel movements in patients with opi-
oid-induced constipation. Despite the wealth of laxa-
tives available to treat constipation, an estimated
54% of patients treated for OBD do not achieve the
‘desired result’ with medication even half the time
(13). Perhaps this limited efﬁcacy should not be sur-
prising in the context of the absence of treatments
speciﬁcally designed for the treatment of OBD. Avail-
able laxatives do not target the underlying cause of
OBD; furthermore, they are unpredictable, have a
potential for over-use and dependency (both psycho-
logical and physical), and are associated with a range
of side effects (see Table 2) (13,36,47).
In practice, stool softeners such as docusate
sodium are commonly administered to patients with
OBD; they are also prescribed prophylactically to
patients on opioid regimens. Such agents are gener-
ally very well tolerated, but seldom achieve relief of
opioid-induced constipation when used alone. There-
fore, one of the most common regimens prescribed
is a stool softener plus a stimulant laxative (e.g.
senna) (13). Patients who do not respond well to this
regimen are often offered a mild osmotic agent,
lubricant or cathartic laxative. Bulk-forming laxatives
should be recommended with caution because of the
risk of exacerbating constipation, leading to intestinal
obstruction unless adequate ﬂuid intake is main-
tained. Therefore, bulk-forming agents are relatively
contraindicated in cancer patients and older patients
taking opioids for pain control.
Table 2 Common laxatives and side effects (13)
Laxative Adverse effects Mechanism of action
Stool softeners and emollients
e.g. dioctyl sodium, docusate sodium
Few side effects, mainly bitter taste and nausea Lubricates and softens stools
Stimulants and irritants e.g. senna
and bisacodyl
Electrolyte imbalance, dermatitis, melanosis coli Alters intestinal mucosal permeability;
stimulates muscle activity and ﬂuid secretions
Osmotic laxatives e.g. lactulose,
magnesium salts, sorbitol
Electrolyte imbalance; excessive gas; hypermagnesaemia,
hypocalcaemia and hyperphosphataemia in patients
with renal dysfunction; dehydration
Osmotic effect of salts leads to greater
ﬂuid retention in bowel lumen and a net
increase of ﬂuid secretions in the small intestine
Bulk laxatives e.g. psyllium seed, bran Increased gas; bloating; bowel obstruction if strictures present;
choking if powder not taken with enough liquid
Increased fecal bulk and ﬂuid retained
in the bowel lumen
Non-absorbable solutions
e.g. polyethylene glycol
Nausea; abdominal fullness; bloating Volume lavage
Enema Dehydration, hypocalcaemia and hyperphosphataemia
in patients with renal dysfunction
Reﬂex evacuation
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Constipation is a recognised side effect of opioid use;
however, its impact and the wider condition of OBD
have been underestimated and underappreciated by
healthcare professionals (25,38). In light of this,
more studies speciﬁcally designed to assess the pre-
valence and burden of OBD are required.
Patients with OBD suffer from a broad range of
symptoms which in turn can have a serious deleteri-
ous impact on QoL and the daily activities that
patients feel able to perform (36). In an effort to
relieve the most common and debilitating OBD
symptom, constipation, patients often use laxatives
chronically (which is associated with risks) or alter/
abandon their opioid medication, potentially sacriﬁ-
cing analgesic efﬁcacy (9,38). Therefore, the burden
of OBD stems not only from the direct impact on
QoL and healthcare resources of its many symptoms,
but also from the side effects of treatments taken to
relieve the condition. It is incumbent on the primary
care physician to review patients’ pain medication
requirements regularly and to encourage dialog about
side effects. Although symptomatic management can
provide relief for some patients, there is clearly a need
for new therapies that act upon the underlying mech-
anisms of OBD. Agents that speciﬁcally target the
underlying cause of OBD are currently under investi-
gation. The availability of these investigational agents
may provide additional treatment options for physi-
cians, and patients suffering needlessly from OBD.
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